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Abstract
Toll-like receptors play an important role in innate and adaptive immunity and in balancing immune
responses with tolerance. TLR2 is related to protection against allergies and allergic asthma by
sensing pathogen associated patterns as lipoproteins and lipopeptides. A constant Th1 triggering is
thought to prevent Th2 related disorders.
TLR2 is expressed on a variety of cells, both structural as well as immune cells. Importantly, TLR2
is also expressed on dendritic cells, which are thought to be one of the key players of initiating and
maintaining immune responses. Therefore, TLR2 on dendritic cells is a good target for modulating
immunity either to Th1 or Th2 responses, or induction of tolerance.
TLR2 agonists show high immunomodulatory and adjuvantic capacity. This makes TLR2 agonisation
a promising approach for pharmaceutical intervention of allergic disorders.
Introduction
Since a human homologue to drosophila toll-receptor
had been firstly described [1], the family of TLR increased
in members. Furthermore, knowledge broadens about
TLR, their role in innate and adaptive immunity and their
implication in balancing immune responses with toler-
ance. One possible mechanism herein is suppression of
CD4+CD25+ regulatory T cells, allowing the host to
develop an adequate adaptive immune response against
microbacteria [2].
Formulation of the hygiene hypothesis pointed out an
inverse association of microbial load and Th2 disorders
[3,4]. Additionally, genetic variations in TLR2, but not in
TLR4 [5], seem to sign responsible for an observed protec-
tion of farmers' children from allergy and asthma [6].
These protective actions seem to be of special importance
to start already during pregnancy, when prenatal exposure
to farm stables upregulates TLR expression of neonatal
cells [7].
On the other hand, smoking during pregnancy attenuates
TLR-mediated immune responses, possibly increasing the
risk for the offspring to develop allergies and asthma [8].
TLR2 is expressed on a variety of cells, both structural as
well as immune cells, in humans and rodents as there are
neutrophils [9], small airway epithelial cells as well as air-
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[12], monocytes [13], macrophages [14], glial cells [15],
murine bone-marrow derived mast cells [16], and B cells
[17,18]. Its expression is inducible by TNF-α and IFN-γ.
Very importantly, TLR2 is also expressed on DCs, which
are thought to be one of the key players of initiating and
maintaining immune responses, and therefore are a good
target cell for modulating immunity either to Th1 or Th2
responses, or induction of tolerance [19-21].
TLR2 in general senses lipopeptides and lipoproteins,
whereby different heterodimers recognise different struc-
tures: diacylated lipopeptides, e.g. MALP-2 [22], require
TLR2/6 [9,23], whereas triacylated lipopeptides, e.g.
Pam3CysSK4, are recognised by TLR2/1 [9] and lipopro-
teins by TLR2/4 [24].
Although effects of TLR2 agonisation are dependent from
age of the experimental animal, such a correlation is not
observed in humans so far [14,25].
Nevertheless, animal models remain a useful tool to
investigate preventive or therapeutic effects related to
TLR2.
Effects of TLR2 agonisation
Administration of MALP-2 into the airways attracts neu-
trophils to the bronchoalveolar space within 24 h. Two to
three days after instillation, macrophages become more
prominent. On macrophages, TLR2 agonists show clear
activating effects [26]. After 72 h, lymphocytes, although
less in number, reach their maximum contribution to cel-
lularity of BALF. These effects revealed after 10 d [27]. Fur-
thermore, changes in lung histology occur after MALP-2
aerosol administration, where the area of bronchus-asso-
ciated lymphoid tissue is increased. The functional rele-
vance of this finding remains to be investigated [28,29].
Immunostimulation in allergy and allergic 
asthma
TLR2 agonisation bears the potency to both inhibit and
promote development of immune responses and is there-
fore manifold in its implementation.
Mycoplasma infections prevent asthma, an effect which is
partly dependent on the TLR2-IFN-γ -pathway [30]. This
finding lead to the development of small Mycoplasma-
derived compounds for potential pharmacological inter-
vention of allergic diseases. A modulation of an already
existing allergy could be achieved by using such Myco-
plasma-derived compounds, as for example MALP-2.
Intratracheal treatment with this TLR2/6 agonist in com-
bination with the Th1-cytokine IFN-γ clearly reduced
AHR, eosinophilia and Th2 cytokines in BALF; however,
neutrophils and IL-12p70 were induced [31]. Likewise,
treatment with a synthetic TLR2/1 ligand reduced total
cell as well as eosinophil counts in the BALF, IL-4 and IL-
5 levels as well as AHR. These reductions were independ-
ent from IL-10 and TGF-β [32], implicating rather a shift
to a Th1 reaction than an induction of tolerance to be
responsible for these observations. Additionally, TLR2/4
agonisation during allergen challenge in sensitised mice
prevented allergic asthma. On DCs, IL-12 and TNF-α were
induced, which by itself induces IFN-γ production of T
lymphocytes. As a result, eosinophils, IL-4 and IL-13 were
reduced, while neutrophil counts and IFN-γ were elevated,
and no increased activation of Th1-lymphocytes could be
detected [24]. However, also the contrary effect could be
observed: TLR2/1 agonisation aggravated allergic asthma
when administered during the initial phase of the
immune reaction. The type of TLR stimulation during this
early phase seems to be a determinant for the polarisation
of the adaptive immune response [33]. When TLR2 lig-
ands were administered during the efferent phase in a
murine model of allergic conjunctivitis, the infiltration of
eosinophils was suppressed, but rather by inducing a
CD4+ cells apoptosis than by inducing a Th1 response
[34]. Investigations in an in vitro model of allergy demon-
strated an induction of TNF-α and IL-10 synthesis, but not
IL-12, when blood derived DCs were stimulated with
MALP-2 [35]. All these examples demonstrate the various
implementations of TLR2 agonisation, either for shifting
Th2 towards Th1, aggravating Th2 or induction of toler-
ance.
Its high immunomodulatory capacity as an adjuvant is
further emphasised in experimental vaccination against
HIV and measles [36-39]. This makes TLR2 agonisation a
promising approach for pharmaceutical intervention.
TLR2 expression and function is influenced by adminis-
tration of steroids, e.g. dexamethasone. On human airway
smooth muscle cells, upregulation by cytokines as IFN-γ
and TNF-α is potentiated; however, dexamethasone alone
suppresses receptor expression [10]. This might be an
explanation of infectious exacerbations occurring in ster-
oid treated asthma, in contrast to viral exacerbations
mediated via TLR3 [11].
Conclusion
TLR2 is an important receptor in innate and adaptive
immunity and related to protection against allergic disor-
ders in humans. Due to their high immunomodulatory
and adjuvantic capacity, TLR2 agonists bear manifold
implications. Therefore, TLR2 agonists may provide
potent new strategies either for prevention or treatment of
allergies and allergic asthma.Page 2 of 4
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